EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors

Christine M. Fillmore, Chunxiao Xu, Pooja T. Desai, Joanne M. Berry, Samuel P. Rowbotham, Yi-Jang Lin, Haikuo Zhang, Victor E. Marquez, Peter S. Hammerman, Kwok-Kin Wong and Carla F. Kim ()
Additional contact information
Christine M. Fillmore: Stem Cell Program, Boston Children’s Hospital
Chunxiao Xu: Dana-Farber Cancer Institute
Pooja T. Desai: Stem Cell Program, Boston Children’s Hospital
Joanne M. Berry: Stem Cell Program, Boston Children’s Hospital
Samuel P. Rowbotham: Stem Cell Program, Boston Children’s Hospital
Yi-Jang Lin: Harvard Medical School
Haikuo Zhang: Dana-Farber Cancer Institute
Victor E. Marquez: Chemical Biology Laboratory, National Cancer Institute, National Institutes of Health
Peter S. Hammerman: Dana-Farber Cancer Institute
Kwok-Kin Wong: Dana-Farber Cancer Institute
Carla F. Kim: Stem Cell Program, Boston Children’s Hospital

Nature, 2015, vol. 520, issue 7546, 239-242

Abstract: A subset of lung cancer cells with EGFR or BRG1 mutations shows selective sensitivity to a combination of EZH2 inhibitors with topoisomerase II inhibitors such as the commonly used chemotherapeutic drug etoposide.

Date: 2015
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/nature14122 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:520:y:2015:i:7546:d:10.1038_nature14122

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature14122

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().